At present the prevalence of heart failure rises along with aging of the population. Current heart failure therapeutic options are directed towards disease prevention via neurohormonal antagonism (␤-blockers, angiotensin 
Introduction
We are currently witnessing an increase in prevalence of heart failure as result of population aging and improvement in the therapy of cardiovascular diseases. Heart failure affects 4-5 million people in the United States and its prevalence has a direct relationship to age, ranging from 0. 4-2% in the adult population and rising to 5-10% in patients aged more than 65 years [1, 2] . The incidence of heart failure is increasing, as reflected by the statistics of hospital admissions and visits to clinics. The prognosis of heart failure is still poor with mortality similar or even higher than with many common types of cancer, 5-year mortality being 56% for men and 45% for women [3] [4] [5] [6] [7] .
At present the heart failure dynamic is viewed from the perspective of evolution from subclinical pathological changes towards clinical syndromes. Thus [9] 
. This definition underscores the existence of a group of patients with poor prognosis, increased risk for clinical events, and most importantly, compromised quality of life despite available treatment. These patients are in desperate need of new effective therapeutic options and should be included in future research initiatives.
In this article we will review two out of many newly emerging strategies in cardiovascular therapy -metabolic modulation and cellular therapy.
Metabolic modulation
A renewed interest in heart failure metabolism has arisen mainly as a result of newly emerging therapies that hold great promise. Combining old theories with new discoveries in myocardial enegetics is challenging because there exist a multitude of data that often appear contradictory. In order to more clearly summarize the current understanding of metabolism in the failing heart, normal cardiac metabolism should first be reviewed.
Metabolism in the normal heart
The metabolism in the cardiomyocyte can be divided into several steps: (i) substrate uptake and oxidation; (ii) oxidative phosphorylation and adenosine triphosphate (ATP) production and (iii) ATP transfer and utilization (Fig. 1) .
Substrate uptake and oxidation
In a healthy heart 10-40% of acetyl-coenzyme A (acetyl-CoA) comes from oxidation of pyruvate that is the end product of aerobic glycolysis [10] . Intracellular glucose comes from two sources: extracellular glucose and intracellular glycogen stores. Glucose transport across the sarcolemma is controlled by the transmembrane gradient and by the number of glucose transporters (mainly present. Insulin and ischemic states stimulate translocation of GLUT-4 into the sarcolema increasing the rate of glucose uptake [11, 12] . Another potent stimulus for GLUT-4 translocation especially during ischemic conditions is activation of adenosine monophosphate activated protein kinase, which regulates the socalled insulin-independent ischemia-induced glucose uptake [13, 14] [15] [16] [17] .
The rate of fatty acid uptake on the other hand is directly proportional to the concentration in plasma [18, 19] [20, 21] . Fatty acids are transported into the cytosol by either passive diffusion or by protein mediated transport performed by fatty acid translocase or plasma membrane fatty acid binding protein [22, 23] [25] [26] [27] .
Oxidation of fatty acids occurs in mitochondria. The fatty acids are transported across the impermeable mitochondrial membrane by carnitine-dependent transport system [19] . This system is controlled by the CPT-I. CPT-I is inhibited by the key regulator of fatty acid oxidation, malonyl CoA, which is formed as result of acetylCoA carboxylation by acetyl-CoA carboxylase [28, 29] 
Metabolism in heart failure
Once heart failure develops major metabolic derangements occur ( [32] . It is known that during foetal and immediate newborn stages the primary substrate for energy production is glucose as well as lactate [33, 34] . This condition changes to favour fatty acid oxidation within days after birth [35] . Of interest, the volume-overloaded newborn heart has lower expression of enzymes involved in the regulation of fatty acid metabolism suggesting stagnation in the 'foetal state' [36] . In the mature heart, 60-70% of acetyl-CoA is derived from fatty acid oxidation and only 10-40% is produced from pyruvate [37, 38] . Other minor substrates for myocardium in normal conditions that become increasingly important during starvation or with poorly controlled diabetes are ketone bodies. In the ketotic state myocardial fatty acid and glucose uptake and oxidation are inhibited through poorly clarified mechanisms [18, 39] .
Changes that affect cardiac metabolism in heart failure involve all steps in the process:
Changes in substrate utilization
The results of the studies on substrate utilization in heart failure are diverse. The majority supports the concept that in early heart failure there is a normal or slightly increased rate of fatty acid oxidation with down-regulation and actually switch to glucose utilization during late stages of heart failure [32, 39, 40] . When during the course of heart failure this switch occurs, is not completely established. Studies with the canine microembolization model or canine rapid pacing model of heart failure suggest that the changes in substrate utilization are late phenomena [41, 42] .
Heart failure creates a hyperadrenergic state that favours an increased plasma level of fatty acids. The abundance of fatty acids creates a state of local insulin resistance by activating protein kinase C-␤ that phosphorylates the insulin receptor making it inactive [43] . Insulin resistance appears to promote the development of heart failure or it can be a result of heart failure as suggested by a study of canine model of cardiomyopathy that developed myocardial insulin resistance [44] [45] [46] [47] . The role of insulin resistance in heart failure pathogenesis requires more attention, especially in the setting of available data that show improvement of heart failure in patients treated with glucagon-like peptide-1 infusion [48] . Also the role of diuretic-induced insulin resistance should be more thoroughly investigated given present evidence of increased mortality associated with chronic diuretic use among patients with heart failure [49, 50] . [51, 52] .
Effects on oxidative phosphorylation
Metabolic inefficiency in heart failure becomes manifest as consumption of a greater amount of oxygen with no translation into greater cardiac work due to increased production of heat rather than ATP. In a failing heart the mitochondria are unable to efficiently perform their major task of oxidative phophorylation due to disruption of the membrane, defective activity of ETC complexes and low capacity of oxidative phosphorilation [53, 54] .
Defective structure of mitochondria in heart failure was reported in canine as well as in human hearts [53, 55] . The degree of injury manifested as matrix depletion and membrane disruption appears to have a direct relationship with the levels of plasma norepinephrine and the severity of left ventricular dysfunction [53] .
The data concerning defective ETC complexes in heart failure are conflicting with regard to activity of the specific complex affected or whether there is a general dysfunction of ETC rather than one attributable to a single complex. Measurements of respiratory complex activity in heart failure patients showed decreased activity at the level of complexes I, III and IV [53, 56] . In the canine rapid pacing model of heart failure a decreased level of activity was found in complexes III, IV and I [57, 58] . In animals models the defects in ETC complexes III, IV were shown to correlate linearly with the concentration of TNF-␣ in serum and administration of anti-tumor necrosis factor-␣ agent partially prevented the defects [32] .
The existing evidence brings to light the concept that in heart failure a significant defect is created at the level of ETC.
The low capacity of oxidative phosphorylation in heart failure is multifactorial, but is clearly related to the substrate that is predominantly used in this deficient state. The mechanical power of the heart is less at a given rate of oxygen consumption when fatty acids are oxidized rather than glucose [59] . The mechanisms behind this process are unclear but several findings suggest a partial explanation. It is becoming clear that in heart failure the differential expression of enzymes of the fatty acid oxidation pathway is higher relative to the ones for glycolysis [60] . A potential role in this is attributed to nuclear-receptor transcription factors, of which the most studied is the PPAR family. As mentioned previously, PPAR-␣ activates transcription of genes encoding enzymes for ␤-oxidation of fatty acids. PPAR's role in the pathogenetic process of heart failure is not completely understood. It may facilitate switching of substrate utilization. In the rabbit model of volume overload hypertrophic heart failure there was no downregulation in PPAR-␣ protein expression or in the expression of enzymes of fatty acid oxidation, but the uptake and oxidation of fatty acids was increased [61] . In a rat infarction model of heart failure a significant decrease in mRNA expression of PPAR-␣ was 
Changes in ATP transport and utilization The energetic state of the heart is not determined by ATP concentration per se. The primary energy reserve in myocardium is phosphocreatine. In situations when ATP utilization exceeds its production the utilization of phosphocreatine is a way to maintain a steady level of ATP.
In advanced heart failure the levels of ATP and phosphocreatine are both decreased [69, 70] . The previously proposed sequence of events most likely is as follows: initially there is a decrease in phosphocreatine levels indicative of a mismatch in ATP production and use. Afterwards the decrease in ATP and creatine levels follows [71] . The phosphocreatine-to-ATP ratio seems to be better predictor of overall and cardiovascular mortality than New York Heart Association (NYHA) class and left ventricular function [72] .
In conclusion, at present myocardial metabolism in heart failure has been extensively studied but major controversies persist. Medications that influence metabolism in heart failure ( [95] . The magnitude of this process varies among different reports, ranging from 18% to none [95] [96] [97] [103, 104] [107] . Adult stem cell implantation for myocardial recovery was initially performed in animals and quickly translated in human beings [108] . Basically a variety of stem and progenitor cell populations could theoretically be used for cardiomyoplasty. [109] . Despite the fact that the myotubes do not beat in synchrony with the rest of the heart due to inability to couple electromechanically with the cardiomyocytes, studies in animal models of myocardial infarction have reported beneficial effects on both systolic and diastolic performance [110] [111] [112] . Major concern regarding skeletal myoblasts implantation is the possible occurrence of arrhythmias. This occurs through several mechanisms including electrical heterogeneity of action potentials and electrotonic stimulation of cardiac cells [113] . Despite incomplete knowledge regarding their engraftment skeletal myoblasts were the first cells used clinically for cardiac repair in a patient with severe ischemic heart failure with resultant evidence of viability and contraction of the graft (on positron emission tomography and echocardiography respectively) as well as symptomatic improvement [114] . Afterwards a series of non-randomized studies showed improvement in LVEF and symptoms [115] . But as mentioned earlier regarding animal studies, the concern regarding arrhythmias was raised in human studies as well after 4 out 10 patients in one trial experienced ventricular arrhythmias requiring placement of an implantable cardioverter [116] [117] . In vivo administration of human ESC may give rise to teratomas or other unacceptable cardiac complications [118] [119] [120] . Due to risks associated with the broad differentiation potential of ESC only a few studies used these cells in an uncommitted state to repair myocardial infarction [121] . [123, 124] [127] . Once [136] . [140] . Reports in animals demonstrate that MSC home to the heart as well [141] . Their fate in the heart is not completely elucidated and varies in different reports ranging from formation of cardiomyocytes and coronary vessels to differentiation into fibroblasts [142, 143] . Interestingly, MSC engraft in the normal heart and remain quiescent but viable and do not participate in the physiological turnover of myocytes. This raises the possibility of trafficking of MSC from bone marrow via the blood stream to the heart and their storage for possible future activation in response to injury.
. Moreover the mobilization of host cells into myocardium is enhanced after sustaining myocardial infarction [98]. Anversa's group succeeded in demonstrating that in addition to differentiated cardiomyocytes there are committed cardiac stem cells (CSCs) that reside in myocardium and give rise to small developing myocytes [99, 100]. It is not clear yet if these cells are resident cells with potential to replicate or these are migrant bone marrow-derived stem cells. This work was authenticated by identification of a resident population of cardiogenic precursor cells in rats, mice and human beings that express isl1ϩ gene that was initially described in embryonic mesodermal cells that were committed to myocardial lineage [101]. A new concept developed currently is that the heart is a dynamic self-renewing organ. This revolutionizes our understanding of heart pathology as well as the potential for therapy. In a healthy heart there is a continuous turnover of parenchymal cells that is supported by the stem cell compartment. This process is sufficient to maintain cellular homeostasis and normal pump function under physiologic conditions. Unfortunately this mechanism is overwhelmed by powerful injury stimuli as ischemia, pressure or volume overload. With increased pressure or volume load the heart remodels through a combination of mechanisms including myocyte hypertrophy and proliferation, myocyte apoptosis and necrosis [102, 103]. In hypertrophic cardiomyopathy the number of cardiomyocytes often exceeds the number of cells in a normal heart [102]. But with further evolution of the disease there is a modest reduction in myocyte number that cannot explain the degree of deterioration in ventricular function. Possibly this deterioration is due to the accumulation of old poorly contracting cells and formation of scars

Skeletal muscle myoblasts
The first cells used for cardiomyoplasty were the skeletal muscle myoblasts. Skeletal myoblasts are also known as satellite cells localized under the basal membrane of mature muscular fibres and are able to differentiate into myotubes with a phenotypic switch towards slow-twitch fibres when transplanted into an infarct scar
In an attempt to avoid teratoma formation ESC have been partially differentiated in vitro before their implantation into the injured heart [122]. ESCs appear to differentiate into immature cardiomyocytes but whether or not these immature cells can reach adult characteristics is not clear
Bone marrow derived adult stem cells
The fact that stem cells exist in postnatal period was described in the 1960s when Till and McCulloch discovered clonogenic bone marrow cells [126]. The proof of origin of these cells was obtained when a single murine haematopoietic stem cell (HSC) reconstituted all blood cell types following transplantation into lethally irradiated animals
Mesenchymal stem cells (MSC) In the stroma of bone marrow there is a subset of non-HSCs that has the potential to differentiate into cells of mesenchymal origin
Endothelial progenitor cells (EPCs)
EPCs are a subset of bone marrow derived stem cells that are able to acquire endothelial phenotype [144] . These [146, 147] . This is a double-edged sword because there are reports linking angiogenesis and atherogenesis; moreover, CD34 cells are found in atherectomy specimens retrieved from in-stent restenosis [148] . This risk must be weighed against the possible beneficial effect via angiogenesis when EPCs are delivered through intracoronary infusion. On the other hand reports regarding differentiation into cardiomyocytes are contradictory. Some studies demonstrate the differentiation of EPCs into cardiomyocytes whereas others do not confirm this possibility [149, 150] .
Currently available variable data regarding differentiation of bone marrow derived cells into cardiomyocytes is still contradictory but the majority of the evidence supports the beneficial effect that implantation of these cells has on cardiac function. This observation raises the question of whether improvement in cardiac performance regardless of the underlying mechanism should be the primary objective of cell therapy?
Cardiac stem cells
In the last years a distinct population of stem cells has been identified as being resident in the heart -the CSCs.
CSCs are Lin-cells that express c-Kit, MDR1 or Sca-1 antigens [99] . These cells are multipotent in vitro and give rise to cardiomyocyte, endothelial cells and smooth muscle cells in vivo [151] . CSCs participate in physiologic cardiomyocyte turnover and maintain the cellular homeostasis of the heart. Myocardial aging and heart failure develops once replicative senescence of CSCs becomes apparent [152] [131, 150, 154] . Many reports demonstrated another possible mechanism that of cell fusion being responsible for the observed phenotypic changes [155] . Because the number of new cardiomyocytes derived from exogenously delivered bone marrow stem cells is extremely low in order to produce the frequently reported functional improvement another proposed mechanism is stem cell mediated paracrine effect. This effect may trigger vasculogenesis, activation of resident CSC, inhibition of native cardiomyocyte apoptosis and changes in extracellular matrix composition [156] . This hypothesis is indirectly supported by the finding that transplanted human MSC into the brain of mice increased the expression of trophic factors that stimulate the proliferation of endogenous neural stem cells [157] .
To date there is an increasing pool of preclinical evidence for efficacy of stem cell therapy but paradoxically we still do not really understand the underlying mechanism of its action. 
Clinical applications of stem cells
